{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:06:26Z","timestamp":1790593586208,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes and obesity, yet their ocular safety profile remains contested. The longer-acting semaglutide has been repeatedly linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) and, in situations of rapid glycemic correction, to early deterioration of diabetic retinopathy, while shorter-acting drugs such as liraglutide and exenatide show much weaker signals. This review explores the pharmacological underpinnings of this difference by combining three lines of evidence: biased agonism and trafficking at the receptor level, cell-type-specific signaling microenvironments, and a recently proposed hemodynamic mechanism based on GLP-1RA-mediated changes in intracranial pressure. The ocular liabilities of GLP-1RAs may be influenced by a multifactorial interplay between ligand-dictated receptor occupancy profiles, cell-type-specific signaling milieu, and individual anatomical vulnerabilities. This model makes testable predictions and has implications for drug choice, risk stratified monitoring, and the development of future agonists with enhanced ocular safety. Key areas for future research include head-to-head comparisons of different GLP-1RAs' signaling in specific ocular cell types and the risk-benefit equation in non-diabetic individuals using these drugs for weight loss.<\/jats:p>","DOI":"10.3389\/fmed.2026.1957367","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:50:49Z","timestamp":1790592649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework"],"prefix":"10.3389","volume":"13","author":[{"given":"Huili","family":"Li","sequence":"first","affiliation":[{"name":"Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengke","family":"Peng","sequence":"additional","affiliation":[{"name":"Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxi","family":"Lei","sequence":"additional","affiliation":[{"name":"Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4\u2005mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2\u2005mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.preteyeres.2008.11.002","article-title":"Ischemic optic neuropathy","volume":"28","author":"Hayreh","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc25-1929","article-title":"GLP-1 receptor agonists and risk of optic nerve or vision-threatening events in patients with type 2 diabetes or cardiometabolic diseases: a meta-analysis of randomized controlled trials","volume":"49","author":"Li","year":"2026","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-017-0213-3","article-title":"Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis","volume":"17","author":"Jingi","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"Hba1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajo.2026.04.021","article-title":"Glucagon-like peptide-1 receptor agonists and risk of systemic and ocular vascular complications in patients with type 2 diabetes and diabetic retinopathy","volume":"288","author":"Shah","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies","volume":"21","author":"Zheng","year":"2023","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"dgz069","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe type 2 diabetes study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1861940","DOI":"10.1155\/2022\/1861940","article-title":"GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway","volume":"2022","author":"Wei","year":"2022","journal-title":"J Diabetes Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.7150\/ijms.20962","article-title":"GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1\/2-HDAC6 signaling pathway","volume":"14","author":"Cai","year":"2017","journal-title":"Int J Med Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00592-023-02135-7","article-title":"The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy","volume":"60","author":"Oezer","year":"2023","journal-title":"Acta Diabetol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/JCMA.0000000000001370","article-title":"Ocular complications from glucagon-like peptide-1 receptor agonists: clinical evidence, potential mechanisms, and clinical recommendations","volume":"89","author":"Wu","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ICU.0000000000001137","article-title":"Glucagon-like peptide-1 receptor agonists and the eye","volume":"36","author":"Zhang","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1111\/dom.70952","article-title":"Optic ischaemic neuropathy in incretin-based therapy: a comparative analysis of real-world safety data","volume":"28","author":"Kakkar","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.ophtha.2026.04.008","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the north American neuro-ophthalmology society and the American academy of ophthalmology","volume":"133","author":"DeParis","year":"2026","journal-title":"Ophthalmology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07312-2","article-title":"Retinal and optic nerve measures after initiation of empagliflozin plus metformin versus metformin alone in early type 2 diabetes: a prospective observational comparative study","author":"Argon","year":"2026","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul Pept"},{"key":"B42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.molmet.2021.101181","article-title":"Spatiotemporal GLP-1 and GIP receptor signaling and trafficking\/recycling dynamics induced by selected receptor mono- and dual-agonists","volume":"49","author":"Novikoff","year":"2021","journal-title":"Mol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.3390\/ijms26157239","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling: making the case for a functionally gs protein-selective GPCR","volume":"26","author":"Lymperopoulos","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"110604","DOI":"10.1016\/j.jbc.2025.110604","article-title":"Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion","volume":"301","author":"Pearce","year":"2025","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101166","DOI":"10.1016\/j.jot.2026.101166","article-title":"Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT\/mTOR inhibition","volume":"59","author":"Lin","year":"2026","journal-title":"J Orthop Translat"},{"key":"B50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.pharep.2018.10.003","article-title":"Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-\u03b1 stimulated human retinal pigment epithelial cells","volume":"71","author":"Garczorz","year":"2019","journal-title":"Pharmacol Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1021\/acs.jafc.4c08978","article-title":"Blueberry anthocyanin extracts (BAEs) protect retinal and retinal pigment epithelium function from high-glucose-induced apoptosis by activating GLP-1R\/akt signaling","volume":"73","author":"Li","year":"2025","journal-title":"J Agric Food Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"118409","DOI":"10.1016\/j.biopha.2025.118409","article-title":"Semaglutide ameliorates retinal vascular permeability destruction in diabetic retinopathy by AnxA2-mediated MMP-9 activation and basement membrane remodeling","volume":"190","author":"Xu","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.peptides.2018.05.003","article-title":"Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products","volume":"105","author":"Lin","year":"2018","journal-title":"Peptides"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/975032","article-title":"Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1)","author":"Puddu","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.3390\/ijms26083704","article-title":"Liraglutide attenuates FFA-induced retinal pigment epithelium dysfunction via AMPK activation and lipid homeostasis regulation in ARPE-19 cells","volume":"26","author":"Tsou","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"119635","DOI":"10.1016\/j.biopha.2026.119635","article-title":"GLP-1 receptor agonist-induced transient retinal perfusion delay and its potential mediation by intracranial pressure","volume":"201","author":"Lee","year":"2026","journal-title":"Biomed Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaan0972","DOI":"10.1126\/scitranslmed.aan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield","year":"2017","journal-title":"Sci Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e70358","DOI":"10.1111\/ene.70358","article-title":"Efficacy and safety of GLP-1 and dual GIP\/GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis","volume":"32","author":"Stefanou","year":"2025","journal-title":"Eur J Neurol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01616412.2026.2640121","article-title":"Potential therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis","author":"Song","year":"2026","journal-title":"Neurol Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"125711","DOI":"10.1016\/j.jns.2025.125711","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis","volume":"480","author":"Ahmed","year":"2026","journal-title":"J Neurol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/jnis-2025-024139","article-title":"Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study","volume":"18","author":"Debiec","year":"2026","journal-title":"J Neurointerv Surg"},{"key":"B64","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1212\/cont.0000000000001586","article-title":"Treatment and monitoring of idiopathic intracranial hypertension","volume":"31","author":"Chen","year":"2025","journal-title":"Continuum (Minneap Minn)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12987-025-00652-x","article-title":"Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats","volume":"22","author":"Jensen","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"B66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/head.70005","article-title":"Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: a systematic review","volume":"66","author":"de Oliveira","year":"2026","journal-title":"Headache"},{"key":"B67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","article-title":"Pathogenesis of nonarteritic anterior ischemic optic neuropathy","volume":"23","author":"Arnold","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"110562","DOI":"10.1016\/j.exer.2025.110562","article-title":"Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress","volume":"259","author":"B\u00f6hm","year":"2025","journal-title":"Exp Eye Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/iovs.67.2.25","article-title":"Semaglutide protects retinal ganglion cells against rotenone-induced degeneration via improved glucose metabolism","volume":"67","author":"Mouhammad","year":"2026","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"108271","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamaophthalmol.2025.3821","article-title":"Glucagon-like peptide-1 receptor agonists and age-related macular degeneration","volume":"143","author":"Ahuja","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.oret.2025.12.016","article-title":"Rate of age-related macular degeneration in patients prescribed glucagon-like peptide-1 receptor agonists or other weight loss therapies","volume":"10","author":"Myers","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"B74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.66.5.15","article-title":"Glucagon-like peptide 1 receptor agonist stimulation inhibits laser-induced choroidal neovascularization by suppressing intraocular inflammation","volume":"66","author":"Machida","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2026.05.034","article-title":"Semaglutide and neovascular age-related macular degeneration among adults with type 2 diabetes: an OHDSI network study","author":"Cai","year":"2026","journal-title":"Ophthalmology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10565-016-9371-8","article-title":"Autophagy regulates death of retinal pigment epithelium cells in age-related macular degeneration","volume":"33","author":"Kaarniranta","year":"2017","journal-title":"Cell Biol Toxicol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1038\/s41467-024-50500-z","article-title":"The AKT2\/SIRT5\/TFEB pathway as a potential therapeutic target in non-neovascular AMD","volume":"15","author":"Ghosh","year":"2024","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1957367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:50:50Z","timestamp":1790592650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1957367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":78,"alternative-id":["10.3389\/fmed.2026.1957367"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1957367","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1957367"}}